SCHEMBL18220132

SCHEMBL18220132

COCCNS(=O)(=O)/C(C#N)=C/c1ccc(-c2ccc3cc(N4CCOCC4)ccc3c2)o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.53
KDM4E B2RXH2 7/20 0.53
HPGD P15428 6/20 0.53
GAA P10253 6/20 0.53
APP P05067 3/20 0.48
MAPT P10636 8/20 0.47
KMT2A Q03164 6/20 0.47
MEN1 O00255 5/20 0.47
USP2 O75604 2/20 0.47
HTT P42858 2/20 0.47
LMNA P02545 5/20 0.42
SMN1; SMN2 Q16637 2/20 0.39
MAPK1 P28482 1/20 0.38
THRB P10828 1/20 0.38
NPC1 O15118 1/20 0.38
TNNI3 P19429 1/20 0.38
TNNT2 P45379 1/20 0.38
RAB9A P51151 1/20 0.38
TNNC1 P63316 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18220138 0.93 APP (0.46) ALDH1A1KDM4EHPGDGAAAPP
SCHEMBL24076142 0.92 MAPT (0.51) ALDH1A1KDM4EHPGDGAAAPP
SCHEMBL18220129 0.92 APP (0.47) ALDH1A1KDM4EHPGDGAAAPP
SCHEMBL18220145 0.85 KMT2A (0.67) ALDH1A1KDM4EHPGDGAAAPP
SCHEMBL18220135 0.85 ALDH1A1 (0.49) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL18220242 0.85 HPGD (0.40) ALDH1A1KDM4EHPGDGAAAPP
SCHEMBL24068226 0.85 MAPT (0.44) ALDH1A1KDM4EHPGDGAAAPP
SCHEMBL18219867 0.85 APP (0.63) ALDH1A1KDM4EHPGDGAAAPP
SCHEMBL24076143 0.84 MAPT (0.44) ALDH1A1KDM4EHPGDGAAAPP
SCHEMBL18220165 0.84 APP (0.48) ALDH1A1KDM4EHPGDGAAAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-20210371390-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2021-12-02 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 ALDH1A1 4151/4885KDM4E 4807/4885HPGD 4282/4885
US-20210371390-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 ALDH1A1 4151/4885KDM4E 4807/4885HPGD 4282/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 ALDH1A1 4151/4885KDM4E 4807/4885HPGD 4282/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA ALDH1A1 4226/4885KDM4E 4804/4885HPGD 4311/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA ALDH1A1 4226/4885KDM4E 4804/4885HPGD 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.